Cytokinetics Inc (CYTK)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -526,244 | -389,000 | -215,314 | -127,290 | -121,692 |
| Revenue | US$ in thousands | 7,530 | 72,481 | 53,988 | 39,865 | 20,245 |
| Pretax margin | -6,988.63% | -536.69% | -398.82% | -319.30% | -601.10% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-526,244K ÷ $7,530K
= -6,988.63%
Cytokinetics Inc's pretax margin has been negative for the past five years, indicating that the company's operating expenses and losses have exceeded its revenues before accounting for taxes. The pretax margins have shown a downward trend from -452.93% in 2019 to -6,988.63% in 2023. This suggests that the company has been experiencing significant losses relative to its revenue, with the most recent data reflecting a substantial decline in profitability. The consistently negative pretax margins raise concerns about the company's ability to generate profits and manage its cost structure effectively. Overall, Cytokinetics Inc's pretax margin analysis highlights significant financial challenges and the need for strategic interventions to improve its financial performance.
Peer comparison
Dec 31, 2023